抗磷脂综合征相关弥漫性肺泡出血:法国26例系列研究
这项法国多中心回顾性研究纳入26例符合悉尼标准的抗磷脂综合征(APS)合并明确弥漫性肺泡出血(DAH)患者,其中50%为灾难性APS(CAPS)。DAH即刻预后良好(完全缓解69%),但复发率54%,无CAPS者复发风险更高(HR 6.8),CAPS患者长期死亡率更高。
要点
- APS相关DAH以三联抗体阳性(77%)和血栓史(88%)常见,27%以DAH为首发表现。
- 完全缓解率69%,但54%患者在中位1.8年后复发。
- 动脉血栓史、TIA/卒中、机械通气和三联抗体阳性与DAH复发相关。
核心结论
- DAH即刻预后良好,以抗凝和激素治疗为主,但复发常见。
- CAPS患者长期死亡率更高,而无CAPS者DAH复发风险更高。
- 三联抗体阳性和/或动脉血栓表型患者更易复发,即使接受抗凝治疗。
研究设计与样本
- 法国多中心回顾性研究,纳入26例符合悉尼标准且有明确DAH病史的APS患者。
主要发现
- 26例中女性15例(58%),中位年龄45.5岁(95%CI 35-58.1)。
- 23例(88%)有血栓事件史(6例动脉),13例(50%)为CAPS。
- 22例(85%)接受抗凝治疗,22例(85%)接受激素治疗,8例(31%)接受免疫抑制治疗。
- 18例(69%)达到完全缓解,14例(54%)在中位1.8年(95%CI 1.1-3.6)后复发。
关键数值与推荐
- DAH复发风险因素:动脉血栓史(HR 4.6,95%CI 1.2-17)、TIA或卒中(HR 7.8,95%CI 2.2-28)、DAH期间机械通气(HR 6.1,95%CI 0.99-37)及三联抗磷脂抗体阳性。
- 多变量分析显示无CAPS者较CAPS者DAH复发风险更高(HR 6.8,95%CI 1.0-45.3;P=0.048)。
- CAPS患者总体死亡率1年7.7%、5年37.1%;无CAPS患者无死亡。
临床怎么用
- APS相关DAH主要采用抗凝和激素治疗,即刻预后良好。
- 对三联抗体阳性或动脉血栓表型患者应警惕DAH复发,即使已抗凝。
- CAPS患者需关注长期死亡风险,无CAPS者需关注DAH复发风险。
局限性
- 回顾性多中心研究,样本量小(26例)。
- 部分风险因素置信区间宽,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Diffuse alveolar haemorrhage (DAH) is a rare and poorly understood manifestation of antiphospholipid (AP) syndrome (APS). This study describes the clinical presentation, treatment and prognosis of DAH in APS with or without catastrophic APS (CAPS). METHODS: A retrospective multicentre French study includes all APS patients diagnosed according to the Sydney criteria with a history of definite DAH. RESULTS: Of the 26 patients included, 15 (58%) were female (median age, 45.5 years; 95% CI, 35-58.1); 23 (88%) patients had a history of thrombotic events (6 arterial), and 13 (50%) had CAPS. Twenty (77%) were triple-positive for APL antibodies, 5 (19%) had systemic lupus erythematosus, and DAH was inaugural for 7 (27%) patients. Twenty-two patients (85%) were treated with anticoagulants, 22 (85%) with steroids and 8 (31%) with immunosuppressive therapy. Complete remission was achieved in 18 (69%) cases. DAH relapses occurred in 14 patients (54%) after a median of 1.8 (95% CI 1.1-3.6) years. Risk factors for DAH relapse were histories of arterial thrombosis (hazard ratio (HR) 4.6, 95% CI 1.2-17), transient ischaemic attack or stroke (HR 7.8, 95% CI 2.2-28), mechanical ventilation during DAH episode (HR 6.1, 95% CI 0.99-37) and triple APL positivity. Multivariate analysis showed a higher risk of DAH relapse in patients without (vs with) CAPS (HR 6.8, 95% CI 1.0-45.3; P = 0.048). Overall mortality was higher in patients with CAPS (7.7% at 1 year and 37.1% at 5 years); no patients without CAPS died. CONCLUSION: The immediate prognosis of DAH, mainly treated with anticoagulants and steroids, was good. Patients with CAPS had a higher mortality rate in the long-term follow-up. Triple-positive and/or arterial phenotype patients more frequently experienced DAH relapses even when treated with anticoagulants.
引用
- Grobost V, Ramos M, Yelnik C, et al. Diffuse alveolar haemorrhage in antiphospholipid syndrome: a French series of 26 patients. Rheumatology (Oxford). 2026. PMID: 41390974. doi:10.1093/rheumatology/keaf658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。